Ivermectin treatment may improve the prognosis of patients with COVID-19
et al., Archivos de Bronconeumología,
risk of death, 87.1% lower, RR 0.13, p = 0.02, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%), NNT 17.
risk of ICU admission, 89.5% lower, RR 0.11, p = 0.007, treatment 1 of 115 (0.9%), control 11 of 133 (8.3%), NNT 14.
risk of progression, 83.5% lower, RR 0.17, p < 0.001, treatment 3 of 115 (2.6%), control 21 of 133 (15.8%), NNT 7.6.
risk of no recovery, 87.1% lower, RR 0.13, p = 0.02, treatment 1 of 115 (0.9%), control 9 of 133 (6.8%), NNT 17.
hospitalization time, 40.0% lower, relative time 0.60, p < 0.001, treatment 115, control 133.
time to viral-, 73.3% lower, relative time 0.27, p < 0.001, treatment 115, control 133.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Khan et al., 24 Sep 2020, retrospective, Bangladesh, peer-reviewed, median age 35.0, 8 authors, dosage 12mg single dose.
Cartas Científicas / Arch Bronconeumol. 2020;56(12):816–830
María Teresa Gómez-Hernández a,∗ , Nuria M. Novoa a ,
Patricia Antúnez b , Marcelo F. Jiménez a
∗ Corresponding author.
E-mail address: firstname.lastname@example.org
Service of Thoracic Surgery, Salamanca University Hospital,
b Service of Anatomical Pathology, Salamanca University Hospital,
Ivermectin Treatment May Improve the
Prognosis of Patients With COVID-19
El tratamiento con ivermectina puede mejorar el pronóstico de
los pacientes con COVID-19
The pandemic coronavirus disease 19 (COVID-19), caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has been spread rapidly worldwide with considerable morbidity
and mortality. COVID-19 patients have various clinical presentations: asymptomatic, exhibit mild flu-like symptoms, be severely
ill or death.1,2 In addition to elder age and comorbidities, higher
levels of D-dimer and C-reactive protein (CRP) and lower levels of
lymphocyte and eosinophil as well as a cytokine storm are associated with disease severity in COVID-19 patients.3–6 The virus load
may be a main determinant underlying the pathological diversity
in COVID-19 patients.1,2,6 Thus, an effective antiviral treatment is
essential to improve the prognosis of patients with COVID-19.7 In
the absence of specific anti-SARS-CoV-2 agents, various drugs with
antiviral potential are now used to contain the virus in COVID-19
patients. Ivermectin, a US FDA-approved anthelminthic, has garnered enormous interest for treating COVID-19 as it is safe and cheap
and has strong antiviral activities against board ranges of viruses
including SARS-CoV-2 in vitro.8–10 Despite the widespread use of
ivermectin, to our knowledge, there is currently no published clinical reports of ivermectin in COVID-19 patients. Here, we assessed
the clinical efficacy of ivermectin in COVID-19 patients.
This retrospective study enrolled a total of 325 consecutive
patients with SARS-CoV-2 infection confirmed by polymerase chain
reaction (PCR) of nasal swabs in SK hospital, a unit dedicated
to COVID-19 at Mymensingh Medical College Hospital (MMCH),
Mymensingh, Bangladesh, from April to June 2020. Of these, the
present study included 248 adult COVID-19 patients free from
any other serious pathological conditions: 115 received ivermectin
plus standard care (SC), while 133 received only SC. Remaining 77
patients who were under 18 years of age or transferred from other
facilities and received different management approaches including
partial hospital stays or treated with different therapeutic agents
prior to hospital admission were excluded from the analysis. The
two groups were compared in terms of time to SARS-CoV-2 negativity, disease progression (develop pneumonia to severe respiratory
distress), duration of hospital stays, and mortality rate. Ivermectin
was given once at dose of 12 mg within 24-h after hospital admission. SC was provided as required and included antipyretics for
fever, anti-histamines for cough, and antibiotics to control secondary infection. The study was approved by MMCH and informed
consent was obtained from all patients or their relatives before
starting treatment. Categorical variables are shown as frequencies
and percentages and continuous variables as the median and interquartile range (IQR). Differences with 95% confidence intervals (CI)
were computed to show the level of certainty...
is less effective
Please send us corrections, updates, or comments.
c19early involves the extraction of over 100,000 datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Vaccines and treatments are complementary. All practical, effective, and safe
means should be used based on risk/benefit analysis. No treatment, vaccine, or
intervention is 100% available and effective for all current and future
variants. We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC
provide treatment protocols.